Pharmaceuticals

Jack Patterson examines how new off-the-shelf CAR T-cell therapy and optimized monoclonal antibodies could disrupt the multiple sclerosis treatment paradigm.

As regulatory demands surge, the EVERSANA and Pulse Infoframe alliance signals a vital shift from siloed trials to continuous real-world data pipelines.

Boehringer Ingelheim’s new quarterable PREVICOX tablets offer precise dosing for small dogs and slash supply chain waste, proving small tweaks yield big gains.

Bright Path Labs is using military-backed continuous-flow technology to reshore critical drug manufacturing, challenging the dominance of overseas APIs.

BridgeBio is using cultural icons to find undiagnosed heart disease in Black men. It’s a brilliant public health move—and a shrewd business strategy.

In an era of pharmaceutical supply chain disruptions and rising FDA warning letters, one manufacturer's pristine compliance streak offers a rare blueprint.

Following severe adverse events linked to compounded glutathione, industry accreditors are cracking down on the booming, loosely regulated IV therapy market.

As biopharma pivots to high-dose subcutaneous therapies, conventional delivery systems are hitting a mechanical wall. Early 'systems thinking' is the new mandate.

Alpha Cognition is set to present compelling real-world data on ZUNVEYL, revealing how this novel prodrug could reduce psychotropic use in long-term care.

With a newly published pediatric case study and a recent $50 million funding lifeline, Quoin Pharmaceuticals is racing to deliver the first approved therapy for Netherton Syndrome.

Margaret Mitchell explores how a German biotech's moss-grown protein could shift the paradigm in complement-mediated diseases from inhibition to restoration.

With a $50B market in play, NFL Biosciences is leveraging predictive biomarkers and novel neurobiology to disrupt the stagnant smoking cessation landscape.

Vaxcyte is arming itself with $1 billion in fresh capital to challenge Pfizer and Merck, leveraging a dual-tranche financing strategy to scale manufacturing.

Equillium's Phase 1 trial of EQ504 in Australia signals a strategic shift in ulcerative colitis care, prioritizing targeted mucosal healing.

As psychedelic medicine nears FDA approval, MAPS and a new practitioner alliance are building the nonprofit infrastructure needed to scale therapy safely.

With Phase 3 enrollment complete, vTv Therapeutics aims to succeed where pharmaceutical giants failed in the quest for a Type 1 diabetes pill.

Pacira BioSciences taps Molteni Farmaceutici to navigate Europe’s fragmented market, trading direct control for a capital-efficient rollout of EXPAREL.

With new Canadian government funding, Vasomune Therapeutics is reformulating its vascular leak drug for the frontlines of military and civilian trauma.

Ajinomoto Bio-Pharma Services' latest rebrand signals a vital shift, prioritizing deep technical mastery in complex therapies over the one-stop-shop model.

New clinical data published in the Journal of Fungi reveals Moberg Pharma's MOB-015 overcomes terbinafine resistance, unlocking massive market potential.